Skip to Main content Skip to Navigation
Journal articles

Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis

Abstract : Corticosteroids and azathioprine provide complete response with good tolerance in most patients for the treatment of autoimmune hepatitis (AIH). Although some patients require second-line treatments, scarce data and side effects hamper consensus on them. Inflammatory bowel diseases (IBD) yielded increasing consideration for azathioprine metabolism and the use of 6-Mercaptopurine (6-MP) or 6-Thioguanine (6-TG), which both exhibit a more direct metabolism to the active metabolite of azathioprine: 6-thioguanine nucleotides (6-TGN).3 Data regarding thiopurines substitution as a second-line therapy for AIH are limited and even more so regarding 6-TG. We herein report our experience with 6-TG after azathioprine failure or intolerance.
Complete list of metadatas

Cited literature [7 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01717742
Contributor : Laurent Jonchère <>
Submitted on : Thursday, March 29, 2018 - 10:01:21 AM
Last modification on : Thursday, July 5, 2018 - 2:29:16 PM
Long-term archiving on: : Thursday, September 13, 2018 - 11:37:22 AM

File

Safety and Efficacy of 6-thiog...
Files produced by the author(s)

Identifiers

Citation

Clémence Legué, Ludivine Legros, Solène Kammerer-Jacquet, Caroline Jézequel, Pauline Houssel-Debry, et al.. Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, WB Saunders, 2018, 16 (2), pp.290-291. ⟨10.1016/j.cgh.2017.07.032⟩. ⟨hal-01717742⟩

Share

Metrics

Record views

324

Files downloads

271